Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional) | PAR 19 064

Opportunity Information: Apply for PAR 19 064

The National Institutes of Health (NIH) grant opportunity titled "Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)" (Funding Opportunity Number: PAR 19-064; CFDA 93.279) is designed to fund short, exploratory, pilot, or feasibility studies that need to happen quickly in order to capture fleeting public health or policy moments related to drug use and addiction services. It uses the NIH R21 mechanism, which is typically intended for early-stage or exploratory work rather than large, definitive trials, and it allows clinical trials but does not require them. The central idea is speed: applicants have to show that their research question is genuinely time-sensitive and that waiting for a standard review and funding timeline would likely mean missing the opportunity to answer the question well, such as when a policy change is imminent or a sudden local crisis is unfolding.

The FOA targets five priority areas within substance use epidemiology and health services research. First, it supports rapid research responses to sudden and severe emerging drug issues, such as an unexpected spike in opioid overdoses or a surge in synthetic cannabinoid harms within a specific community. Second, it funds research that can respond to emerging marijuana trends, especially those tied to changing laws and policy environments, where rapid evaluation might inform decisions while policies are still being implemented or adjusted. Third, it encourages quick-turnaround studies on unexpected and time-sensitive prescription drug abuse research opportunities, for example when a state or local government introduces a new program, regulation, monitoring approach, or enforcement effort that creates a narrow window to assess impact. Fourth, it covers urgent medical system issues, including timely opportunities to study how addiction prevention and treatment services are delivered as health care systems evolve, reorganize, or adopt new models of care. Fifth, it includes time-sensitive research opportunities arising in criminal justice or juvenile justice settings, particularly when system-level changes, structural reforms, or new policies affect substance use outcomes and access to health care services for justice-involved populations.

A distinguishing requirement is that proposals must make a clear case that the knowledge to be gained is perishable in the sense that it depends on being studied during a short window. The FOA explicitly emphasizes the need for expedited review and funding so that studies can be launched quickly enough to observe conditions before, during, or immediately after a major change, outbreak, or intervention. In practice, this means applicants are expected to justify why rapid NIH action is necessary, what would be lost if the work started later, and how the project is designed to deliver meaningful findings despite being exploratory in scope.

The opportunity is categorized as a discretionary grant in the education and health funding activity area, and it is administered by NIH. The listed award ceiling is $200,000. While the source text does not specify the number of expected awards, the overall framing suggests support for multiple small, nimble projects rather than a few large ones. The original closing date provided is October 8, 2021, and the FOA record shows a creation date of November 9, 2018, which is useful context for understanding the timing of the announcement itself (and also signals that applicants should verify current status and any reissued versions if they are looking to apply now).

Eligibility is broad and includes many types of U.S.-based organizations and government entities. Eligible applicants include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations other than federally recognized tribal governments; public housing authorities and Indian housing authorities; nonprofits with or without 501(c)(3) status (excluding institutions of higher education in those nonprofit categories as stated); for-profit organizations other than small businesses; and small businesses. The FOA also highlights additional eligible applicant types such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, Indian/Native American Tribal Governments other than federally recognized, and U.S. territories or possessions.

At the same time, the FOA draws firm boundaries around foreign participation. Non-domestic (non-U.S.) entities and foreign institutions are not eligible to apply, and non-domestic components of U.S. organizations are not eligible. In addition, foreign components as defined by the NIH Grants Policy Statement are not allowed, meaning the research activities must remain domestic in scope and execution under NIH definitions. This is important for teams that might otherwise plan international data collection, overseas sites, or formal foreign institutional involvement.

Overall, this FOA is aimed at researchers and organizations that can move quickly, have access to relevant data sources or settings, and can produce actionable, early evidence about emerging drug-related problems, policy shifts, or system changes. The best-fit projects are typically those that can document real-time trends, evaluate rapid policy or program rollouts, and generate timely findings that inform public health and service delivery decisions while there is still an opportunity to act on the results.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279.
• This funding opportunity was created on 2018-11-09.
• Applicants must submit their applications by 2021-10-08. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $200,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 19 064

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: